Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $15.6 million.

  • Evoke Pharma's Liabilities and Shareholders Equity rose 1056.88% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.6 million, marking a year-over-year increase of 4320.33%. This contributed to the annual value of $17.5 million for FY2024, which is 14784.46% up from last year.
  • Evoke Pharma's Liabilities and Shareholders Equity amounted to $15.6 million in Q3 2025, which was up 1056.88% from $16.1 million recorded in Q2 2025.
  • Evoke Pharma's Liabilities and Shareholders Equity's 5-year high stood at $19.3 million during Q1 2021, with a 5-year trough of $7.1 million in Q4 2023.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $12.5 million (2024), whereas its average is $13.0 million.
  • Per our database at Business Quant, Evoke Pharma's Liabilities and Shareholders Equity skyrocketed by 31604.98% in 2021 and then crashed by 5322.19% in 2022.
  • Evoke Pharma's Liabilities and Shareholders Equity (Quarter) stood at $10.6 million in 2021, then increased by 12.09% to $11.9 million in 2022, then tumbled by 40.36% to $7.1 million in 2023, then surged by 147.84% to $17.5 million in 2024, then decreased by 10.67% to $15.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $15.6 million for Q3 2025, versus $16.1 million for Q2 2025 and $16.4 million for Q1 2025.